May 7, 2019: The University of Michigan is leading a Big Ten Cancer Research Consortium study that will test the immunotherapy drug nivolumab combined with the anti-CSF-1R monoclonal antibody cabiralizumab in patients with relapsed or refractory peripheral T cell lymphoma (PTCL). The study is now open for accrual at the University of Michigan Rogel Cancer Center. The study, BTCRC-HEM16-085, “Phase II study of nivolumab and the antagonistic CSF-1R monoclonal antibody cabiralizumab (BMS-986227) in patients with relapsed/refractory peripheral T cell lymphoma,” will help researchers determine the number of patients whose tumors shrank after receiving this therapy, and how long this response lasts before the tumors start to grow again.... Read More
May 3, 2019: The Big Ten Cancer Research Consortium will host meetings for the Big Ten CRC Foundation, Cancer Center Directors, Steering Committee, and Clinical Trial Working Groups during ASCO 2019. Read More
May 1, 2019: Investigator Spotlight: Ardaman Shergill, MD, University of Illinois Research interests: Dr. Shergill has a broad clinical practice where she treats patients with a variety of cancers. Her mission: Bring high quality, evidence-based, state-of-the-art care to all her patients, and deliver it in the most compassionate way possible. Her interest in cancer is due to having lost loved ones to the disease, giving her a unique and humbling insight into a patient’s experience with the illness. Dr. Shergill is interested in helping develop and improve access to novel promising therapeutic advances for her patients so they may benefit from the latest research that is occurring in the rapidly changing field of oncology. She has extensive experience in clinical trials and... Read More
April 29, 2019: A Big Ten Cancer Research Consortium phase I/II study is testing the safety and efficacy of combining ixazomib and romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). The study is now open for accrual at the University of Michigan Rogel Cancer Center, Rutgers Cancer Institute of New Jersey, the University of Illinois Cancer Center in Chicago, and Holden Comprehensive Cancer Center at the University of Iowa. Read More
April 16, 2019: In this month’s Across the Consortium, the Big Ten CRC highlights a variety of initiatives, including treatment for children with leukemia, research for future vaccines against cancer, and research to prolong the lives of those fighting some of the most deadly cancers; and we honor cancer advocates who have lost their own battles with cancer. Read More
April 1, 2019: Investigator Spotlight Salma Jabbour, MD, Rutgers Cancer Institute of New Jersey Educational background BA, University of Virginia MD, University of Maryland School of Medicine Internship, University of Maryland Medical Center Residency in Radiation Oncology, Johns Hopkins School of Medicine Research interests I am interested in developing novel therapies for the treatment of lung cancers and gastrointestinal cancers in combination with radiation therapy. Many of these diseases still require significant improvements in outcomes, and breakthroughs such as immunotherapy may help patients live longer and control their cancers when combined with radiation therapy. Read More
March 25, 2019: In this month's Across the Consortium, the Big Ten CRC highlights research to detect cancer cells early in their development, and other advances from our member institutions. We also congratulate those who received hard-earned grants and leadership positions. Read More
March 8, 2019: A phase I Big Ten Cancer Research Consortium study for adult patients with relapsed or refractory Classical Hodgkin lymphoma is open for accrual at Masonic Cancer Center, University of Minnesota; the University of Illinois Cancer Center; the University of Wisconsin Carbone Cancer Center; and the University of Iowa Holden Comprehensive Cancer Center. The study, BTCRC-HEM15-027, will help determine the safety (maximum tolerated dose) and efficacy of ruxolitinib, which blocks the main pathway dysregulated in Hodgkin lymphoma, when combined with the immunotherapy drug nivolumab. Read More
March 1, 2019: Investigator Spotlight Shihuan Kuang, PhD, Purdue University Center for Cancer Research Educational background PhD in Physiology and Cell Biology: University of Alberta Research interests My lab mainly aims to understand the molecular regulation of stem cells in the adult skeletal muscle and adipose tissues, and how deregulation of certain signaling pathways underlie diseases including cancer. Read More
Subscribe to the Big Ten CRC Newsletter
X
Facebook
YouTube